Saturday, March 26, 2016 10:22:13 PM
Eventually the FDA has to begin removal of non-ADF opiods. Or leave non-ADF opiods for Clinical settings ONLY.
Nasrat said there has to be a few competitors for each opiod, each immediate or extended release delivery system. If the FDA does not do this everyone is wasting their time investing in ADF opiods.
Can't stop abuse if you don't take away what they are abusing.
Elite with SequestOx and Eaglet with Oxagio will have the IR ADF Oxy
Modality covered. What would an FDA mandate do to share price if 2-3 companies end up with 91 % of all new opiod RXs(IR opiods for acute pain)
The big question is When? 2017 or 2018?
Eventually first generation ADFs like OxyContin maybe removed and replaced by better products, this maybe a long time from now.
There is hope for more than just a couple $dollars a share.
Like a Couch says, A perfect storm is brewing !
Big Surprises are possible with Elite.
I expect ELI202 to be a generic PErcoset ADF(maybe not a great ADF but an ADF) one bead ER oxy/APAP which is resistant to snorting(nasal) abuse only. We may see FDA filing before SequestOx Approval?
Epic's new ER oxy will be removed from the market and replaced in a few years with Elites ER ADF oxycodone ELI-201.
Don't give up on ELI-216 ER 24 hour(once/day) ADF oxycodone.
I see a partnership developing with this one. SequestOx launch will give potential partners the confidence they need to jump on board.
Nasrat said there has to be a few competitors for each opiod, each immediate or extended release delivery system. If the FDA does not do this everyone is wasting their time investing in ADF opiods.
Can't stop abuse if you don't take away what they are abusing.
Elite with SequestOx and Eaglet with Oxagio will have the IR ADF Oxy
Modality covered. What would an FDA mandate do to share price if 2-3 companies end up with 91 % of all new opiod RXs(IR opiods for acute pain)
The big question is When? 2017 or 2018?
Eventually first generation ADFs like OxyContin maybe removed and replaced by better products, this maybe a long time from now.
There is hope for more than just a couple $dollars a share.
Like a Couch says, A perfect storm is brewing !
Big Surprises are possible with Elite.
I expect ELI202 to be a generic PErcoset ADF(maybe not a great ADF but an ADF) one bead ER oxy/APAP which is resistant to snorting(nasal) abuse only. We may see FDA filing before SequestOx Approval?
Epic's new ER oxy will be removed from the market and replaced in a few years with Elites ER ADF oxycodone ELI-201.
Don't give up on ELI-216 ER 24 hour(once/day) ADF oxycodone.
I see a partnership developing with this one. SequestOx launch will give potential partners the confidence they need to jump on board.
You Can Tell A Man's Character By The Way He Treats Those Who Can Do Nothing For Him
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
